Time-Course Changes in Bone Metabolism Markers and Density in Patients with Osteoporosis Treated with Romosozumab: A Multicenter Retrospective Study
Authors:
- Kazuhide InageKIKazuhide Inage
- Sumihisa OritaSOSumihisa Orita
- Yawara EguchiYEYawara Eguchi
- Yasuhiro ShigaYSYasuhiro Shiga
- Masao KodaMKMasao Koda
- Yasuchika AokiYAYasuchika Aoki
- Toshiaki KotaniTKToshiaki Kotani
- Tsutomu AkazawaTATsutomu Akazawa
- Takeo FuruyaTFTakeo Furuya
- Junichi NakamuraJNJunichi Nakamura
- Hiroshi TakahashiHTHiroshi Takahashi
- Miyako Suzuki-NaritaMSMiyako Suzuki-Narita
Open Access
- 1 January 2021
- journal article
- research article
- Published by XMLink in Yonsei Medical Journal
- Vol. 62 (9) , 829-835
Abstract
Inage K, et al. Yonsei Med J. 2021 Sep;62(9):829-835. https://doi.org/10.3349/ymj.2021.62.9.829Keywords
This publication has 7 references indexed in Scilit:
- Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumabOsteoporosis International, 2019
- Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trialThe Lancet, 2017
- Romosozumab Treatment in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 2016
- Inhibition of osteoblast function in vitro by aminobisphosphonatesJournal of Cellular Biochemistry, 2008
- Combination anabolic and antiresorptive therapy for osteoporosis: Opening the anabolic windowCurrent Osteoporosis Reports, 2008
- Prevalence of osteoporosis in patients requiring spine surgery: incidence and significance of osteoporosis in spine diseaseOsteoporosis International, 2007
- Anabolic Therapy for OsteoporosisWomen's Health, 2007